Aktuellt
SENASTE
Redeye comments on Spago Nanomedical's Q2 report, which came without any surprises. We judge the market has lost sight of Spago and that the share could rally to our Base Case upon SpagoPix licensing and Tumorad entering the clinic.
LÄS MER
